Capstone Therapeutics Corp., a biotechnology company, develops and sells novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone602-286-5520
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
OptionableNot Optionable
Capstone Therapeutics (OTCMKTS:CAPS) Frequently Asked Questions
What is Capstone Therapeutics' stock symbol?
Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS."
How were Capstone Therapeutics' earnings last quarter?
Capstone Therapeutics Corp (OTCMKTS:CAPS) announced its quarterly earnings results on Monday, August, 13th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2 million for the quarter. View Capstone Therapeutics' Earnings History.
Has Capstone Therapeutics been receiving favorable news coverage?
Media headlines about CAPS stock have trended somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Capstone Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the next several days.
Who are some of Capstone Therapeutics' key competitors?
Some companies that are related to Capstone Therapeutics include Apricus Biosciences (APRI), OHR Pharmaceutical (OHRP), Stellar Biotechnologies (SBOT), Flex Pharma (FLKS), Pernix Therapeutics (PTX), Praxsyn (PXYN), ContraVir Pharmaceuticals (CTRV), Sonoma Pharmaceuticals (SNOA), Midatech Pharma (MTP), Propanc Biopharma (PPCB), iCo Therapeutics (ICOTF), Integrated BioPharma (INBP), Ritter Pharmaceuticals (RTTR), Parnell Pharmaceuticals (PARNF) and Bioblast Pharma (ORPN).
Who are Capstone Therapeutics' key executives?
Capstone Therapeutics' management team includes the folowing people:
- Mr. John M. Holliman III, Exec. Chairman & Principal Exec. Officer (Age 65)
- Mr. Leslie M. Taeger, Sr. VP, CFO & Principal Accounting Officer (Age 68)
- Dr. Randolph C. Steer, Consultant (Age 69)
- Dr. William M. Wardell M.D., Ph.D., Head of Clinical & Regulatory Review Board (Age 80)
- Ms. Karen Struck, Investor Relations Professional
How do I buy shares of Capstone Therapeutics?
Shares of CAPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capstone Therapeutics' stock price today?
One share of CAPS stock can currently be purchased for approximately $0.0344.
How big of a company is Capstone Therapeutics?
Capstone Therapeutics has a market capitalization of $1.87 million. Capstone Therapeutics employs 2 workers across the globe.
What is Capstone Therapeutics' official website?
How can I contact Capstone Therapeutics?
Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The biotechnology company can be reached via phone at 602-286-5520 or via email at [email protected]
MarketBeat Community Rating for Capstone Therapeutics (OTCMKTS CAPS)
MarketBeat's community ratings are surveys of what our community members think about Capstone Therapeutics and other stocks. Vote "Outperform" if you believe CAPS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPS will underperform the S&P 500 over the long term. You may vote once every thirty days.
